Please activate JavaScript!
Please install Adobe Flash Player, click here for download

Dental Tribune United Kindom Edition

Do you have an opinion or some- thing to say on any Dental Tribune UK article? Or would you like to write your own opinion for our guest comment page? If so don’t hesitate to write to: The Editor, Dental Tribune UK Ltd, 4th Floor, Treasure House, 19-21 Hatton Garden, London, EC1 8BA Or email: lisa@dentaltribuneuk.com Editorial comment Trade name of medicinal product: Duraphat® 50 mg/ml Dental Suspension. Active ingredients: 1ml of suspension contains 50mg Sodium Fluoride equivalent to 22.6mg of Fluoride (22,600ppm F) Indications: Prevention of caries, desensitisation of hypersensitive teeth. Dosage and administration: Recommended dosage for single application: for milk teeth: up to 0.25ml (=5.65mg Fluoride), for mixed dentition: up to 0.40ml (=9.04 Fluoride), for permanent dentition: up to 0.75ml (=16.95 Fluoride). For caries prophylaxis the application is usually repeated every 6 months but more frequent applications (every 3 months) may be made. For hypersensitivity, 2 or 3 applications should be made within a few days. Contraindications: Hypersensitivity to colophony and/or any other constitu- ents. Ulcerative gingivitis. Stomatits. Bronchial asthma. Special warnings and special precautions for use: If the whole dentition is being treated the application should not be carried out on an empty stomach. On the day of application other high fluoride preparations such a fluoride gel should be avoided. Fluoride supplements should be suspended for several days after applying Duraphat®. Interactions with other medicines: The presence of alcohol in the Duraphat® formula should be considered. Undesirable effects: Oedematous swelling has been observed in subjects with tendency to allergic reactions. The dental suspension layer can easily be removed from the mouth by brushing and rinsing. In rare cases, asthma attacks may occur in patients who have bronchial asthma. Legal classification: POM. Product licence number: PL 00049/0042. Product licence holder: Colgate-Palmolive (U.K.) Ltd, Guildford Business Park, Middleton Road, Guildford, Surrey GU2 8JZ. Price: £22.70 excl VAT (10ml tube) Date of revision of text: July 2008. Reference: 1. Marinho VCC, Higgins JPT, Logan S et al. The Cochrane Library 2007, Issue 4. 33% reduction in dmfs and 46% reduction in DMFT1 Apply Colgate Duraphat Fluoride Varnish It’s clinical evidence that sets our varnish apart *based on a number of published clinical studies * 3NewsJuly 30 - August 5, 2012United Kingdom Edition T he 2012 National Dental Nursing Conference - the last before the end of the five-year CPD cycle for those dental nurses who regis- tered before August 2008 - will be held at the Blackpool Hilton on 24 November 2012. The new one day format is being trialled in accordance with dental nurses’ responses to the BADN’s recent survey. “Holding a one day Confer- ence allows us to keep the cost down” said BADN President Nicola Docherty. “This year, with generous sponsorship from the BDTA, the Conference registration fee is less than £50 for BADN members, and offers 4.5 hours of verifiable CPD.” “Topics include the core subjects of decontamination, medical emergencies and ra- diography, as well as oral cancer, hypnodontics, com- munication skills, special care, the end of the cpd cycle and, of course, the keynote address by GDC Chair Kevin O’Brien.” The Conference registra- tion fee also includes lunch, refreshments and a pre-lunch Zumba session. Also in accordance with the survey results, there will be no Presidential Dinner this year. Instead, delegates can join Nicola and other BADN Council members at an infor- mal dinner at iconic fish and chips restaurant Harry Rams- dens, just beneath Blackpool Tower the evening before Con- ference. For more information, visit www.badn.org.uk/conference where there is a link to the on line registration. DT BADN dental nursing conference A s you read this issue of Dental Tribune the biggest event on earth will be in full swing in London and oth- er places across the country. Oh yes – the Olympics are here! And while we cheer on our respective countries we all get to involve our- selvesinthehighsandlowsofcom- petitive sport, as well as become world experts in sports that two weeks ago we had never even heard of! Let’s hope for a fantastic Games and the chance to show the world how great we are! (Come on Team GB! – Ed) Moving back to matters closer to the surgery - con- gratulations to Anna Bradley, who has been confirmed as the Chair of Healthwatch England. The role, which also comes with the honour of be- ing a non-executive Direc- tor of the Care Quality Com- mission, was taken up by Ms Bradley on the 16th July. Healthwatch is the new con- sumer champion for health and social care in England. It will exist intwodistinctforms-Healthwatch England, at national level, and local Healthwatch, at local level. Healthwatch England will be a national body representing the viewsofserviceusersandthepub- lic. It will use these views to influ- ence national policy and provide advice to Monitor, the NHS Com- missioning Board, the Secretary of State and English local authorities, as well as pro- viding leadership and sup- port to local Healthwatch organisations. DT